Brief: Aclaris Therapeutics Announces Positive Results From Phase 1 Trial Of Ati-2138, An Investigational Oral Covalent Itk/Jak3 Inhibitor
18/09/2023 12:17
Sept 18 (Reuters) - Aclaris Therapeutics Inc ACRS.O :
* ACLARIS THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE
1
MULTIPLE ASCENDING DOSE TRIAL OF ATI-2138, AN INVESTIGATIONAL
ORAL COVALENT ITK/JAK3 INHIBITOR
* ACLARIS THERAPEUTICS INC- ATI-2138 WAS GENERALLY WELL
TOLERATED
AT ALL DOSES TESTED IN TRIAL
Source text for Eikon: ID:nGNX2ypknw
Further company coverage: ACRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Aclaris Therapeutics Q3 revenue beats analyst estimates
Brief: Aclaris Therapeutics Q3 Net Income USD -18.51 Million Vs. IBES Estimate USD -23.7 Million
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aclaris Therapeutics Q2 revenue beats analyst estimates